Tandem Technology, Inc.

Tandem Technology, Inc. is a US-based company specializing in automating medication access processes for healthcare providers, thereby enhancing operational efficiency and improving patient care through effective management solutions. Founded in 2023 by Sahir J. Tandem Technology, Inc.

operates from New York, US, focusing on automating prior authorizations and medication access for healthcare providers. In February 2026, Tandem Technology, Inc. raised USD 100 million in venture funding led by Accel, with participation from General Catalyst Partners and Thrive Capital. The venture funding values the company at approximately USD 1 billion post-money.

The company was established by individuals with expertise in healthcare technology, although specific information about the founder's previous ventures is not available. Tandem has no known subsidiaries or parent companies. Tandem offers a comprehensive suite of services designed to streamline the medication access process for healthcare providers and their patients. Their core product focuses on automating prior authorizations (PAs), appeals, enrollment forms, and pharmacy routing, thereby reducing the administrative burden on medical practices.

This service enables healthcare providers to enhance patient care by expediting therapy initiation, ensuring that patients have timely access to necessary medications. Tandem's client base includes healthcare providers across thousands of practices, particularly in the United States, who utilize the platform to enhance operational efficiency and minimize time spent on paperwork, faxes, and phone calls. The end users of Tandem's services are primarily patients requiring medications, as well as the medical professionals who seek to facilitate their access effectively. Tandem generates revenue through partnerships with healthcare providers who utilize its automated medication access services.

The transaction structure typically involves subscription models wherein practices pay for access to the platform’s capabilities, allowing them to manage the prior authorization process more efficiently. While specific pricing plans are not publicly detailed, the service aims to provide a cost-effective solution to practices, thereby enhancing their workflow and patient engagement. By automating key aspects of medication access, Tandem positions itself as a valuable partner in the healthcare ecosystem, allowing providers to focus on patient care while ensuring compliance and efficiency in medication management practices. The company will use the February 2026 funding to hire talent, develop product features, and deepen partnerships across sectors.